Evidence map›Paper›PMID 42689729›Full record

ArticleOncoimmunology2026

Unveiling the immune microenvironment in sinonasal intestinal type adenocarcinoma: new arguments for immunotherapy.

Charles Lépine, Cécile Deleine, Richard Danger, Laura Do Souto Ferreira, Elisabeth Nguyen, Marie-Anne Vibet, Olivier Malard, Nadine Gervois, Karine Renaudin, Anne Jarry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charles LépineNantes Université, CHU de Nantes, Pathology Department, Nantes, France.
Cécile DeleineNantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR1302/EMR6001, Nantes, France.
Richard DangerNantes Université, CHU de Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR1064, Nantes, France.
Laura Do Souto FerreiraNantes Université, CHU de Nantes, Medical Genetic Department, Nantes, France.
Elisabeth NguyenNantes Université, CHU de Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR1064, Nantes, France.
Marie-Anne VibetNantes Université, CHU de Nantes, Research and Innovation Department, Nantes, France.
Olivier MalardNantes Université, CHU de Nantes, Department of Otorhinolaryngology and Head and Neck Surgery, Nantes, France.
Nadine GervoisNantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR1302/EMR6001, Nantes, France.
Karine RenaudinNantes Université, CHU de Nantes, Pathology Department, Nantes, France.
Anne JarryNantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR1302/EMR6001, Nantes, France.ORCID 0000-0002-3489-7800

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sinonasal intestinal-type adenocarcinoma (ITAC) is a rare malignancy strongly associated with occupational exposure to wood dust that shares morphological and molecular similarities with colorectal adenocarcinoma. Standard treatments offer limited benefit for advanced or recurrent disease. It is therefore necessary to develop other strategies, such as immunotherapies, which require a better understanding of the tumor immune microenvironment, are needed. In this study, we investigated the immune microenvironment of ITACs (n

Indexed as

AdenocarcinomaImmunotherapyLymphocytes, Tumor-InfiltratingParanasal Sinus NeoplasmsTumor MicroenvironmentAgedCD8-Positive T-LymphocytesFemaleHumansMacrophagesMaleMiddle AgedPrognosisimmune checkpointsImmunotherapypatient-derived explantssinonasal intestinal type adenocarcinoma (ITAC)transcriptomicstumor immune microenvironment

Identifiers

PMID42689729
PMCPMC13556939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.